#1 Clinical Trials Search in Europe

Methylone

Methylone, a synthetic compound, is currently being investigated in several clinical trials as a potential treatment for Post-Traumatic Stress Disorder (PTSD). These studies aim to evaluate its safety, efficacy, and pharmacological properties. The trials involve different aspects of methylone use, including its effects on PTSD symptoms, long-term efficacy, and potential for abuse. Researchers are also examining its pharmacokinetics and comparing it to other substances like MDMA. These studies could provide valuable insights into methylone’s therapeutic potential and help determine its future role in mental health treatment.

Table of Contents

What is Methylone?

Methylone, also known as 3,4-methylenedioxy-N-methylcathinone or MDMC, is a synthetic compound that is being studied for its potential therapeutic effects[1]. It belongs to a class of substances called synthetic cathinones, which are chemically related to naturally occurring compounds found in the khat plant[1]. Methylone is structurally similar to MDMA (commonly known as ecstasy), a substance that has shown promise in treating certain mental health conditions[1].

Potential Uses of Methylone

The primary focus of current research on methylone is its potential use in treating Post-Traumatic Stress Disorder (PTSD)[2][3][4]. PTSD is a mental health condition that can develop after experiencing or witnessing a traumatic event. Symptoms may include flashbacks, nightmares, severe anxiety, and uncontrollable thoughts about the event.

Researchers are investigating whether methylone can help reduce the severity of PTSD symptoms and improve overall quality of life for patients[3]. Some studies are also looking at its potential effects on depression, which often co-occurs with PTSD[3].

Ongoing Research on Methylone

Several clinical trials are currently underway to evaluate the safety and effectiveness of methylone for PTSD treatment:

  • Long-term studies: Some trials are examining the long-term effects of methylone over a 52-week period[2].
  • Short-term studies: Other trials are looking at the effects of methylone over shorter periods, such as 3-4 weeks of treatment followed by a 6-week follow-up period[3][4].
  • Dosage studies: Researchers are also conducting studies to determine the appropriate dosage and understand how the body processes methylone[5].

How Methylone is Administered

In the clinical trials, methylone is typically administered as an oral capsule. The frequency and duration of treatment vary depending on the specific study:

  • Some trials involve weekly doses for 3-4 weeks[3][4].
  • Other studies may involve single doses to assess immediate effects and how the body processes the drug[5].

Safety and Side Effects

As with any medication under investigation, researchers are closely monitoring the safety of methylone and any potential side effects. Some of the aspects being studied include:

  • Changes in vital signs such as blood pressure, heart rate, and body temperature[1].
  • Effects on mood and perception[1].
  • Potential for abuse or dependence[1].
  • Incidence of adverse events (unwanted side effects)[3].

It’s important to note that the full safety profile of methylone is still being determined through these clinical trials.

Comparison to MDMA

Some studies are comparing methylone to MDMA, which is also being researched for PTSD treatment[1]. Both substances have similar chemical structures and may have comparable effects, but researchers are working to understand the specific differences and potential advantages of methylone.

Future Prospects and Considerations

While the research on methylone for PTSD treatment is promising, it’s important to understand that this medication is still in the experimental stage. More research is needed to fully understand its effectiveness, safety, and long-term effects before it can be considered for widespread use.

Patients interested in participating in clinical trials involving methylone should consult with their healthcare providers to discuss potential risks and benefits, as well as to determine if they meet the eligibility criteria for ongoing studies.

Aspect Details
Purpose of Studies Evaluate safety, efficacy, and pharmacology of methylone for PTSD treatment
Study Designs Various designs including open-label, randomized, placebo-controlled, and dose-finding studies
Administration Oral capsules, typically once weekly for 3-4 weeks
Primary Outcomes Changes in PTSD symptom severity (CAPS-5, PCL-5 scores)
Secondary Outcomes Depression symptoms, disability measures, adverse events, pharmacokinetics
Safety Monitoring Blood pressure, heart rate, body temperature, pupil size, psychiatric symptoms
Comparisons Placebo, different doses of methylone, MDMA (in some studies)
Duration Varies by study, ranging from single-dose to 52-week follow-up
Potential Impact May provide new treatment option for PTSD if proven safe and effective

FAQ

  • What is methylone and why is it being studied? Methylone is a synthetic compound being investigated as a potential treatment for Post-Traumatic Stress Disorder (PTSD). It's being studied because it may have properties that could help alleviate PTSD symptoms and improve patients' quality of life.
  • How is methylone administered in these clinical trials? In most of the trials, methylone is administered orally in capsule form. The dosing schedule varies, but it's typically given once a week for 3 to 4 weeks, depending on the specific study design.
  • What are the main outcomes being measured in these trials? The main outcomes include changes in PTSD symptom severity (measured by scales like CAPS-5 and PCL-5), changes in depression symptoms, effects on disability and impairment, and the incidence of adverse events. Some studies also measure pharmacokinetic parameters like maximum plasma concentration and time to reach it.
  • Are there any comparisons being made to other treatments? Yes, some trials compare methylone to placebo to determine its effectiveness. Additionally, one study compares methylone to MDMA (also known as ecstasy) to assess their relative effects and potential for abuse.
  • What are the potential risks or side effects of methylone? The trials are designed to monitor for adverse events and safety concerns. Common measurements include changes in blood pressure, heart rate, body temperature, and pupil size. Participants are also monitored for any psychiatric symptoms or changes in mood and behavior.

Ongoing Clinical Trials on Methylone

  • Study on the Long-term Effects of Methylone for Treating PTSD in Patients

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Ireland

  • Study of Methylone Treatment for Adults with Post-Traumatic Stress Disorder (PTSD)

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Ireland

Glossary

  • Methylone: A synthetic compound being studied as a potential treatment for Post-Traumatic Stress Disorder (PTSD). It's administered orally in clinical trials.
  • Post-Traumatic Stress Disorder (PTSD): A mental health condition triggered by experiencing or witnessing a terrifying event, characterized by symptoms such as flashbacks, nightmares, and severe anxiety.
  • Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): A structured interview used to assess the severity of PTSD symptoms. Scores range from 0 to 80, with higher scores indicating more severe symptoms.
  • PTSD Checklist for DSM-5 (PCL-5): A 20-item, patient-rated scale used to measure the severity of PTSD symptoms. Scores range from 0 to 80, with higher scores indicating more severe symptoms.
  • Montgomery-Asberg Depression Rating Scale (MADRS): A 10-item, clinician-rated scale used to assess the severity of depression. Scores range from 0 to 60, with higher scores indicating more severe depression.
  • Sheehan Disability Scale (SDS): A 3-item, patient-rated scale that measures disability and impairment across work/school, social life, and family life. Total scores range from 0 to 30, with higher scores indicating greater disability.
  • Treatment-emergent adverse events (TEAEs): Side effects or undesirable experiences that occur after starting a new treatment, which were not present before or have worsened in intensity or frequency.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Maximum plasma concentration (Cmax): The highest concentration of a drug in the blood plasma after administration.
  • Area under the concentration-time curve (AUC): A measure of the total exposure to a drug over time, used in pharmacokinetic studies.
  • MDMA: 3,4-Methylenedioxymethamphetamine, also known as ecstasy, a psychoactive drug sometimes used as a comparison in clinical trials studying methylone.

References

  1. https://clinicaltrials.gov/study/NCT05488171
  2. https://clinicaltrials.gov/study/NCT06237426
  3. https://clinicaltrials.gov/study/NCT06215261
  4. https://clinicaltrials.eu/trial/study-on-methylone-for-treating-post-traumatic-stress-disorder-ptsd-in-patients/
  5. https://clinicaltrials.gov/study/NCT06303648